RituxME: larger double-blind rituximab trial
Fluge Ø et al. · 2019 · Annals of Internal Medicine
Indexed 2026-11-12.
Reported findings and study design
Reported findings
Two induction infusions of 500 mg/m² two weeks apart, then 500 mg at months 3, 6, 9 and 12. Follow-up lasted 24 months.
Dose, route and schedule
Two induction infusions of 500 mg/m² two weeks apart, then 500 mg at months 3, 6, 9 and 12. Follow-up lasted 24 months.
Protocol source ↗ · Original article abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Overall response | 26.0% with rituximab versus 35.1% with placebo (p=0.22). | |
| Fatigue over 24 months | Average difference 0.02 points (95% CI −0.27 to 0.31, p=0.80). | |
| Serious adverse events | 20/77 (26.0%) versus 14/74 (18.9%). |
This trial found no support for clinical benefit from the tested regimen.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- This trial found no support for clinical benefit from the tested regimen.
Related publications may cover the same research program or participants.
Source access
Two induction infusions of 500 mg/m² two weeks apart, then 500 mg at months 3, 6, 9 and 12. Follow-up lasted 24 months.
Source reviewed 2026-11-12.
DOI: 10.7326/M18-1451
Citation and original source
Original source: Fluge Ø et al.. RituxME: larger double-blind rituximab trial Annals of Internal Medicine 2019.
Molekul research summary: https://molekul.io/research/rituximab-rituxme-2019. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry